Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a Dry powder inhaler (DPI) and Respimat device~Exclusion criteria:~* Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug abuse~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Olodaterol (BI1744) Low (Type: EXPERIMENTAL): Low dose inhaled orally once daily from Respimat inhaler
- Olodaterol (BI1744) High (Type: EXPERIMENTAL): High dose inhaled orally once daily from Respimat inhaler
- Tiotropium 18 mcg (Type: ACTIVE_COMPARATOR): 18 mcg inhaled once daily from HandiHaler
- Placebo (Type: PLACEBO_COMPARATOR): Olodaterol placebo and/or Tiotropium placebo inhaled once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).